• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Glytec Awarded 3 Patent Notices for Precision Diabetes Management Apps

by HITC Staff 09/28/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

glytec

Glytec, an innovator in diabetes care management has announced three patent notices of allowance to its growing patent portfolio, affording further protection of the proprietary diabetes technologies associated with its eGlycemic Management System®. 

Glytec offers the only patented and FDA-cleared solution for glycemic management that encompasses insulin dosing decision support for:

1. inpatient AND outpatient settings

2.  intravenous AND subcutaneous insulin therapies,

3.  adult AND pediatric populations, and

4.  patients with AND without diabetes.

The three new allowances will issue as patents over the next 60 days — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to five. The company has more than 30 other U.S. and international patent applications pending.

The three allowed applications that will soon issue as patents recite, among other things, methods and systems to:

– Control blood glucose levels among inpatient and outpatient populations across care settings. This includes: (a) intravenous insulin therapy and transitions to subcutaneous basal or basal-bolus insulin therapy, and (b) the integration of connected devices such as blood glucose meters, insulin pens and infusion pumps.

– Utilize smartphone-based interactivity between and on behalf of patients and providers. This includes: (a) prescriber-initiated communication regarding medication adjustments, (b) alerting of healthcare professionals to out-of-range glycemic measurements, (c) database-driven dietary and carbohydrate recommendations, and (d) management of events that affect blood glucose, such as exercise, travel, changes in circadian rhythms, and menstruation.

– Mitigate diabetes-related and stress-induced hyperglycemia in hospitalized patients. This includes calculations and recommendations for: (a) optimal insulin infusion rates, (b) appropriate time intervals between blood glucose readings, (c) continuous nutritional insulin infusion, and (d) transitions from intravenous insulin therapy to subcutaneous basal or basal-bolus insulin therapy.

“These additional patents reflect another important set of breakthrough advancements made over the company’s now 11-year history, contributing to more effective care for people living with diabetes,” says Robby Booth, Glytec’s Senior Vice President Research & Development. “While we’re pleased and proud to be receiving additional patent protection for a broad array of methods and systems, the unprecedented clinical results our clients are achieving stand as the greatest testimony to the uniqueness of Glytec’s eGMS®.”

Founded in 2006, Glytec has developed a comprehensive eGlycemic Management System®, oreGMS®, which centers on the only FDA-cleared solution for insulin dosing able to support personalized intravenous and subcutaneous therapy for adult and pediatric populations across the entire care continuum.

The solution seamlessly integrates with EMR systems for streamlined use in all inpatient and outpatient settings. It also integrates with connected devices for at-home care managed through telehealth, population health and other value-based programs. The eGMS® employs a cloud-hosted software-as-a-service (SaaS) delivery model, allowing for rapid implementation and anytime/anywhere access.

The efficacy of the eGMS®, including its ability to substantively improve clinical and financial outcomes, has been validated bymore than 55 published studies. Results have included dramatic reductions in lengths of stay, readmissions and A1c levels. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Glytec

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

HLTH 2025 Coverage

HLTH 2025 Day 1 Summary & Insights: AMA Launches AI Governance Center, Google Cloud, Microsoft, ChatGPT for Medicine

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Northwell Health Selects to Deploy Abridge’s Ambient AI Across 28 Hospitals

Northwell Health to Deploy Abridge’s Ambient AI Across 28 Hospitals

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |